A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

← catalyst calendar

NCT07011043 · readout ≤ 254 d

Sponsored by Climb Bio, Inc. (industry) · CLYM — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

30estimated

Sites

Countries

Bulgaria, Georgia, Greece +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-07-10

actual

When the study began enrolling

Primary completion

Apr 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Apr 2027

estimated

The whole study's end, after follow-up

First posted

2025-06-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-27

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Systemic Lupus Erythematosus

Intervention

Drug: Budoprutug — also filed as TNT119

Primary outcomes

what the primary-completion date above is the date OF

Incidence of Treatment-Emergent Adverse Events (TEAEs)

measured Up to Week 24

Incidence of Clinical Laboratory Abnormalities

measured Up to Week 24

Change from Baseline in Systolic Blood Pressure

measured Up to Week 24

Change from Baseline in Diastolic Blood Pressure

measured Up to Week 24

Change from Baseline in Heart Rate

measured Up to Week 24

Change from Baseline in Respiratory Rate

measured Up to Week 24

Change from Baseline in Body Temperature

measured Up to Week 24

Change from Baseline in PR Interval

measured Up to Week 24

Change from Baseline in QRS Duration

measured Up to Week 24

Change from Baseline in QT Interval

measured Up to Week 24

Change from Baseline in QTc Interval

measured Up to Week 24

Permalink · CLYM's whole pipeline · Catalyst calendar · Every registered study · What changed